Knockdown of HPRT for Selection of Genetically Modified Human Hematopoietic Progenitor Cells

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Choudhary, Rashmi ^a,c   Baturin, Dmitry ^a   Fosmire, Susan ^a   Freed, Brian ^b   Porter, Christopher C ^a  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ARTICLE; CELL COMPARTMENTALIZATION; CELL EXPANSION; CELL POPULATION; CELL PROLIFERATION; CELL SELECTION; CELL SURVIVAL; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; GENE SILENCING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; RNA SEQUENCE; SCID MOUSE; UMBILICAL CORD BLOOD;

ANIMALS; ANTIGENS, CD34; CELL LINE; DRUG RESISTANCE; FEMALE; GENE KNOCKDOWN TECHNIQUES; HEMATOPOIETIC STEM CELLS; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LYMPHOCYTES; MICE; MYELOID CELLS; THIOGUANINE; TRANSDUCTION, GENETIC; UMBILICAL CORD;

EID: 84875012329     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059594     Document Type: Article

References (32)

1. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, et al. (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360: 447-458.
2. Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Diez IA, et al. (2010) Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 363: 1918-1927.
3. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
4. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, et al. (2002) Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185-1193.
5. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, et al. (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
6. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
7. Modlich U, Bohne J, Schmidt M, von Kalle C, Knoss S, et al. (2006) Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108: 2545-2553.
8. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, et al. (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696.
9. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, et al. (2006) Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 103: 17372-17377.
10. Abonour R, Williams DA, Einhorn L, Hall KM, Chen J, et al. (2000) Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 6: 652-658.
11. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, et al. (1998) Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 16: 165-172.
12. Hildinger M, Fehse B, Hegewisch-Becker S, John J, Rafferty JR, et al. (1998) Dominant selection of hematopoietic progenitor cells with retroviral MDR1 co-expression vectors. Hum Gene Ther 9: 33-42.
13. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, et al. (1992) Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257: 99-103.
14. Williams DA, Hsieh K, DeSilva A, Mulligan RC, (1987) Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J Exp Med 166: 210-218.
15. Warlick CA, Diers MD, Wagner JE, McIvor RS, (2002) In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model. J Pharmacol Exp Ther 300: 50-56.
16. Corey CA, DeSilva AD, Holland CA, Williams DA, (1990) Serial transplantation of methotrexate-resistant bone marrow: protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 75: 337-343.
17. Cowan KH, Moscow JA, Huang H, Zujewski JA, O'Shaughnessy J, et al. (1999) Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 5: 1619-1628.
18. Maze R, Carney JP, Kelley MR, Glassner BJ, Williams DA, et al. (1996) Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc Natl Acad Sci U S A 93: 206-210.
19. Beard BC, Trobridge GD, Ironside C, McCune JS, Adair JE, et al. (2010) Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest 120: 2345-2354.
20. Giordano FA, Sorg UR, Appelt JU, Lachmann N, Bleier S, et al. (2011) Clonal inventory screens uncover monoclonality following serial transplantation of MGMT P140K-transduced stem cells and dose-intense chemotherapy. Hum Gene Ther 22: 697-710.
21. Davis BM, Koc ON, Gerson SL, (2000) Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood 95: 3078-3084.
22. Zielske SP, Reese JS, Lingas KT, Donze JR, Gerson SL, (2003) In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J Clin Invest 112: 1561-1570.
23. Adair JE, Beard BC, Trobridge GD, Neff T, Rockhill JK, et al. (2012) Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med 4: 133ra157.
24. Erlichman C, Moor M (2001) Carcinogenesis: A late complication of cancer chemotherapy. In: Chabner BA, Longo, D.L., editor. Cancer Chemotherapy & Biotherapy. 3rd ed. Philadelphia: Lippincott Williams & Wilkens. 67-84.
25. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C, (2002) Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 99: 1909-1912.
26. Porter CC, DeGregori J, (2008) Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection. Blood 112: 4466-4474.
27. Pui CH, Relling MV, (2000) Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 109: 13-23.
28. Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, et al. (2007) Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 41: 21-28.
29. Hacke K, Szakmary A, Cuddihy AR, Rozengurt N, Lemp NA, et al. (2012) Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow. Exp Hematol 40: 3-13 e13.
30. Metais JY, Dunbar CE, (2008) The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. Mol Ther 16: 439-449.
31. Rosenfeld C, Goutner A, Choquet C, Venuat AM, Kayibanda B, et al. (1977) Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line. Nature 267: 841-843.
32. Matsuo Y, MacLeod RA, Uphoff CC, Drexler HG, Nishizaki C, et al. (1997) Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia 11: 1469-1477.